A new method of treatment of retinitis pigmentosa/pigmentary abiotrophy.
We report our results of treatment of pigmentary retinal abiotrophy with a drug known in the Soviet Union as Encad. Repeated courses of treatment twice a year for four to 14 years stabilized the pathologic process in more than 60% of 467 treated patients. We provide details of the treatment and specific indications and contraindications.
Katznelson
L A
LA
Moscow Helmholtz Research Institute of Eye Diseases, USSR.
Khoroshilova-Maslova
I P
IP
Eliseyeva
R F
RF
D000293:Adolescent; D000328:Adult; D000818:Animals; D003623:Dark Adaptation; D004305:Dose-Response Relationship, Drug; D004596:Electroretinography / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D009843:Oligoribonucleotides; D010786:Photoreceptor Cells / Q000187:drug effects / Q000648:ultrastructure; D051381:Rats; D012160:Retina / Q000187:drug effects / Q000648:ultrastructure; D012174:Retinitis Pigmentosa / Q000188:drug therapy*; D012265:Ribonucleotides / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
D009843:Oligoribonucleotides; D012265:Ribonucleotides; C031373:ENKAD